Karlijn van Halewijn

Karlijn van Halewijn is a researcher at Erasmus MC, affiliated with the Department of General Practice within the Faculty of Medicine. Her work focuses on improving the management of atopic dermatitis in primary care settings, particularly among children. She is actively involved in clinical research, contributing to evidence-based guidelines and understanding treatment barriers.

Research Interests: Karlijn's research spans primary health care, pediatric dermatology, and chronic skin conditions. She investigates practical aspects of atopic dermatitis management, including topical corticosteroid use, patient and provider attitudes (e.g., corticophobia), and the design and challenges of clinical trials in general practice. Her work emphasizes real-world applicability and patient-centered outcomes.

The recent publications highlight a strong focus on randomized controlled trials, cohort studies, and survey-based research in primary care. Themes include treatment efficacy, recruitment difficulties, and quality of life in pediatric eczema patients. Her research contributes significantly to understanding how dermatological conditions are managed outside specialist settings.

Scientific Contributions:

• Conducted pivotal research on corticosteroid use in children with eczema.
• Explored barriers to clinical trial participation in primary care.
• Contributed to population-level understanding of atopic dermatitis through the Rotterdam Eczema Study.

Advising and Grants: While no formal students or grant funding are listed in the provided text, her role as a doctoral thesis author suggests active research leadership. She likely participates in collaborative projects funded through institutional or national health research programs, given the scale of her studies.

Labs and Teams: Karlijn is part of a multidisciplinary research group at Erasmus MC focused on general practice and dermatology, collaborating with experts in pediatric dermatology and primary care research. Her network includes key figures such as Dr. Suzanne Pasmans and Prof. Peter Bindels, indicating integration into a robust clinical research ecosystem.